With the involvement of the NF-κB signaling pathway, high expression of NKILA can sensitize activated T cells to tumor-induced activation-induced cell death (AICD), resulting in cytotoxic T lymphocyte death and immunological disorders.[82] From this perspective, inhibition of NKILA expression has a facilitative effect on the efficacy of these approaches for treating cancer by immunological means. This evidence concerns the gene NFKB1 and neoplasm.